|
1
|
Harbeck N, Penault-Llorca F, Cortes J,
Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F:
Breast cancer. Nat Rev Dis Primers. 5(66)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Waks AG and Winer EP: Breast cancer
treatment: A review. JAMA. 321:288–300. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Huang J, Chan PS, Lok V, Chen X, Ding H,
Jin Y, Yuan J, Lao XQ, Zheng ZJ and Wong MC: Global incidence and
mortality of breast cancer: A trend analysis. Aging (Albany NY).
13:5748–5803. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gregory RI, Chendrimada TP, Cooch N and
Shiekhattar R: Human RISC couples microRNA biogenesis and
posttranscriptional gene silencing. Cell. 123:631–640.
2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Mycko MP, Cichalewska M, Machlanska A,
Cwiklinska H, Mariasiewicz M and Selmaj KW: MicroRNA-301a
regulation of a T-helper 17 immune response controls autoimmune
demyelination. Proc Natl Acad Sci USA. 109:E1248–E1257.
2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Yu H, Li H, Qian H, Jiao X, Zhu X, Jiang
X, Dai G and Huang J: Upregulation of miR-301a correlates with poor
prognosis in triple-negative breast cancer. Med Oncol.
31(283)2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ma F, Zhang J, Zhong L, Wang L, Liu Y,
Wang Y, Peng L and Guo B: Upregulated microRNA-301a in breast
cancer promotes tumor metastasis by targeting PTEN and activating
Wnt/β-catenin signaling. Gene. 535:191–197. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Li X, Li J, Cai Y, Peng S, Wang J, Xiao Z,
Wang Y, Tao Y, Li J, Leng Q, et al: Hyperglycaemia-induced miR-301a
promotes cell proliferation by repressing p21 and Smad4 in prostate
cancer. Cancer Lett. 418:211–220. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wang YG, Wang T, Shi M and Zhai B: Long
noncoding RNA EPB41L4A-AS2 inhibits hepatocellular carcinoma
development by sponging miR-301a-5p and targeting FOXL1. J Exp Clin
Cancer Res. 38(153)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Li X, Zhong M, Wang J, Wang L, Lin Z, Cao
Z, Huang Z, Zhang F, Li Y, Liu M and Ma X: miR-301a promotes lung
tumorigenesis by suppressing Runx3. Mol Cancer.
18(99)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hu H, Zhang Q, Chen W, Wu T, Liu S, Li X,
Luo B, Zhang T, Yan G, Lu H and Lu Z: MicoRNA-301a promotes
pancreatic cancer invasion and metastasis through the JAK/STAT3
signaling pathway by targeting SOCS5. Carcinogenesis. 41:502–514.
2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
15
|
von Minckwitz G, Huang CS, Mano MS, Loibl
S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A,
Redondo A, et al: Trastuzumab emtansine for residual invasive
HER2-positive breast cancer. N Engl J Med. 380:617–628.
2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
von Minckwitz G, Procter M, de Azambuja E,
Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N,
Clark E, et al: Adjuvant pertuzumab and trastuzumab in early
HER2-positive breast cancer. N Engl J Med. 377:122–131.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Slamon D, Eiermann W, Robert N, Pienkowski
T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et
al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J
Med. 365:1273–1283. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chen Z, Chen LY, Dai HY, Wang P, Gao S and
Wang K: miR-301a promotes pancreatic cancer cell proliferation by
directly inhibiting Bim expression. J Cell Biochem. 113:3229–3235.
2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Xia X, Zhang K, Luo G, Cen G, Cao J, Huang
K and Qiu Z: Downregulation of miR-301a-3p sensitizes pancreatic
cancer cells to gemcitabine treatment via PTEN. Am J Transl Res.
9:1886–1895. 2017.PubMed/NCBI
|
|
20
|
Fang Y, Sun B, Xiang J and Chen Z:
MiR-301a promotes colorectal cancer cell growth and invasion by
directly targeting SOCS6. Cell Physiol Biochem. 35:227–236.
2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang W, Zhang T, Jin R, Zhao H, Hu J,
Feng B, Zang L, Zheng M and Wang M: MicroRNA-301a promotes
migration and invasion by targeting TGFBR2 in human colorectal
cancer. J Exp Clin Cancer Res. 33(113)2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wang M, Li C, Yu B, Su L, Li J, Ju J, Yu
Y, Gu Q, Zhu Z and Liu B: Overexpressed miR-301a promotes cell
proliferation and invasion by targeting RUNX3 in gastric cancer. J
Gastroenterol. 48:1023–1033. 2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xu XD, He XJ, Tao HQ, Zhang W, Wang YY, Ye
ZY and Zhao ZS: Abnormal expression of miR-301a in gastric cancer
associated with progression and poor prognosis. J Surg Oncol.
108:197–202. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zheng JZ, Huang YN, Yao L, Liu YR, Liu S,
Hu X, Liu ZB and Shao ZM: Elevated miR-301a expression indicates a
poor prognosis for breast cancer patients. Sci Rep.
8(2225)2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ohshima J, Haruta M, Arai Y, Kasai F,
Fujiwara Y, Ariga T, Okita H, Fukuzawa M, Hata J, Horie H and
Kaneko Y: Two candidate tumor suppressor genes, MEOX2 and SOSTDC1,
identified in a 7p21 homozygous deletion region in a Wilms tumor.
Genes Chromosomes Cancer. 48:1037–1050. 2009.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tian L, Tao Z, Ye H, Li G, Zhan Z and Tuo
H: Over-expression of MEOX2 promotes apoptosis through inhibiting
the PI3K/Akt pathway in laryngeal cancer cells. Neoplasma.
65:745–752. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ávila-Moreno F, Armas-López L,
Álvarez-Moran A, López-Bujanda Z, Ortiz-Quintero B, Hidalgo-Miranda
A, Urrea-Ramírez F, Rivera-Rosales RM, Vázquez-Manríquez E,
Peña-Mirabal E, et al: Overexpression of MEOX2 and TWIST1 is
associated with H3K27me3 levels and determines lung cancer
chemoresistance and prognosis. PLoS One. 9(e114104)2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhou P, Jiang W, Wu L, Chang R, Wu K and
Wang Z: miR-301a is a candidate oncogene that targets the homeobox
gene Gax in human hepatocellular carcinoma. Dig Dis Sci.
57:1171–1180. 2012.PubMed/NCBI View Article : Google Scholar
|
